GWPH Stock Gains on US Application for Expanded Use of Epidiolex
GWPH stock is trading in the green this morning after GW Pharmaceuticals (NASDAQ:GWPH) filed a supplemental marketing application in the US seeking approval for Epidiolex. Key Trigger The medical cannabis space has grown at a ... [Read]
GWPH Stock Slumps Despite Solid Q3 Earnings Thanks to Epidiolex
GWPH stock is having its worst one-day fall in the past few months despite GW Pharmaceuticals (NASDAQ:GWPH) posting better-than-expected revenue from its flagship product, Epidiolex. Solid Earnings Despite the troubles of the past few months, ... [Read]
The Cost of Epidiolex Is Annouced; A Whopping $32,500 USD A Year
The Epidiolex cost has been revealed. Epidiolex is the first medication derived from cannabis to receive FDA approval. It achieved this milestone in June of this year and marked a turning point in recognizing cannabis ... [Read]
US Gives the Green Light for Marijuana-based Drug for Seizures
Today, the US health regulators announced the approval of Epidiolex — the first prescription drug made from marijuana. This marks a turning point in American federal law with relation to the substance which currently remains illegal ... [Read]